Starting on July 1, 2021 we are reducing the service fee Google Play receives when a developer sells digital goods or services to 15% for the first $1M (USD) of revenue every developer earns each year. With this change, 99% of developers globally that sell digital goods and services with Play will see a 50% reduction in fees. These are funds that can help developers scale up at a critical phase of their growth by hiring more engineers, adding to their marketing staff, increasing server capacity, and more.

While these investments are most critical when developers are in the earlier stages of growth, scaling an app doesn’t stop once a partner has reached $1M in revenue — we’ve heard from our partners making $2M, $5M and even $10M a year that their services are still on a path to self-sustaining orbit. This is why we are making this reduced fee on the first $1M of total revenue earned each year available to every Play developer, regardless of size. We believe this is a fair approach that aligns with Google’s broader mission to help all developers succeed. We look forward to sharing full details in the coming months.

Such nice move won't affect Google income much, as small developers are taking less and less of total Play Store sales. Most of Google income now comes from apps sold by big corporations or startups that are also funded by big organized companies.

Several high-end models will include a Cognitive Processor XR that tries to mimic the way your brain processes images by surveying each frame of video and picking out the most important zones to optimize.

Guys, I perfectly understand that Sony has too many people and lot of them have nothing to do. But it is not so hard to find something useful and nice for them to work on, even fixing such non poetic things like video formats support, proper work with subtitles and so on. Even making general user interface to feel like you did not accidentally run Windows 10 on 486 computer could be already real breakthrough.

But please... get your dirty hands out of touching image. Just show me it as it is, accurate and precise with all the flaws and issues.

The Indian government has developed a bill that will completely ban cryptocurrencies in the country.

Storage, release, mining, trading and transfer will face a fine or criminal liability. At the same time, citizens will be given six months to get rid of cryptocurrency assets. If the bill is passed, India will become the first major economy to completely ban cryptocurrencies.

Of course, Indian government do this not because they love you. Main reasons are ability to avoid taxes and big energy consumption.

Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group (73 (11.03 %) vs. 1548 (15.77%); p=0.001). Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to non‐users (adjusted OR 0.71 (95% CI, 0.52 to 0.99; p=0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; p<0.001), presented a lower BMI (28.77±5.4 vs. 30.37±4.55; p<0.0189) and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%) and COPD (11, 15.07%) than showed the aspirin non‐users (151, 25.64%, p<0.001; 130, 22.07%, p<0.001; and 43, 7.3%, p=0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT‐PCR test results) among aspirin users was significantly shorter, as compared to aspirin non‐users (19.8±7.8 vs. 21.9± 7.9 p= 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (p=0.449). In conclusion, we observed inverse association between the likelihood of COVID‐19 infection, disease duration and mortality and aspirin use for primary prevention.

https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15784